# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Pha...
Truist Securities analyst Srikripa Devarakonda initiates coverage on Protagonist Therapeutics (NASDAQ:PTGX) with a Buy ratin...
JMP Securities analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and lower...
HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the pric...
Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate...
Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%
JP Morgan analyst Brian Cheng maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target...